Bionano Genomics

Bionano Genomics’ Saphyr optical genome mapping platform has demonstrated higher sensitivity than traditional cytogenetic methods in detecting structural variants. The company’s solutions are used globally in clinical research and diagnostics labs. In recent years they have achieved key milestones such as CMS reimbursement coding for OGM tests in the US. Their technology enables comprehensive detection of genomic aberrations that are often missed by sequencing or microarray alone. Revenue reported was $27.9 million for the first nine months of 2024 with an installed base of over 350 systems worldwide as of September that year.